Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Public ClinicalTrials.gov record NCT03809624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 / 2 Study of INBRX-105 and INBRX-105 in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT03809624
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- INBRX-105 - PDL1x41BB antibody Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 29, 2019
- Primary completion
- Oct 2, 2024
- Completion
- Oct 2, 2024
- Last update posted
- Oct 22, 2024
2019 – 2024
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute | Scottsdale | Arizona | 85258 | — |
| City of Hope at Irvine Lennar | Duarte | California | 91010 | — |
| City of Hope | Duarte | California | 91010 | — |
| Valkyrie Clinical Trials | Los Angeles | California | 90069 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| University of Colorado Denver | Denver | Colorado | 80045 | — |
| Emory University - Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Norton Cancer Center | Louisville | Kentucky | 40202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Nebraska Cancer Specialists - Grand Island | Omaha | Nebraska | 68114 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| Providence Cancer Institute | Portland | Oregon | 97213 | — |
| Abramson Cancer Center - University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Abramson Cancer Center at Pennsylvania Hospital | Philadelphia | Pennsylvania | 19104 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37204 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| New Experimental Therapeutics of San Antonio - NEXT Oncology | San Antonio | Texas | 78229 | — |
| START Mountain Region | West Valley City | Utah | 84119 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03809624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2024 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03809624 live on ClinicalTrials.gov.